Objective To investigate the value of long non-coding RNA (lncRNA) TMEVPG1 in the prognosis evaluation of patients with primary immune thrombocytopenia (ITP).

Methods A total of 126 ITP patients were selected as the study group. According to the prognosis of ITP patients, they were divided into poor prognosis group (n=31) and good prognosis group (n=95), and 125 healthy subjects who underwent physical examination during the same period were selected as control group. The relative expression level of lncRNA TMEVPG1 was determined by quantitative real-time polymerase chain reaction (qRT-PCR); correlations of lncRNA TMEVPG1 with platelet count, interferon-γ (IFN-γ), interleukin (IL)-2, IL-4 and IL-10 in ITP patients were explored by Pearson correlation; the factors influencing the prognosis of ITP patients were analyzed by COX regression.

Results Compared with the control group, lncRNA TMEVPG1 level in the study group was significantly decreased (P < 0.05); lncRNA TMEVPG1 level in the poor prognosis group was significantly lower than that in the good prognosis group (P < 0.05). LncRNA TMEVPG1 was positively correlated with platelet count, IL-4 and IL-10, and negatively correlated with IFN-γ and IL-2 (P < 0.05). Lower lncRNA TMEVPG1 was an independent risk factor for poor prognosis in ITP patients (P < 0.05).

Conclusion The decreased level of LncRNA TMEVPG1 is associated with poor prognosis in ITP patients, which can be used as an auxiliary indicator to evaluate the prognosis of ITP patients.